EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
Portfolio Pulse from Vandana Singh
Plus Therapeutics Inc (PSTV) has expanded its supply agreement with Biocept Inc (BIOC) by acquiring an option to exclusively license Biocept's CNSide, a tumor cell capture and enumeration platform. Plus Therapeutics will provide $150,000 in stock to Biocept and has the option for exclusivity for the field of radiotherapy in exchange for a $1.0 million payment before January 1, 2024. The feasibility phase of the study is expected to be completed in 1H of 2024.
September 08, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biocept has expanded its agreement with Plus Therapeutics, which could potentially increase its revenues and profitability.
The expanded agreement with Plus Therapeutics allows Biocept to potentially increase its revenues and profitability. This could lead to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Plus Therapeutics has expanded its agreement with Biocept, which could potentially enhance its product portfolio and increase its market share in the cancer treatment sector.
The expanded agreement with Biocept allows Plus Therapeutics to potentially enhance its product portfolio and increase its market share in the cancer treatment sector. This could lead to increased revenues and profitability in the future, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100